Tag: Pharmaceutical Research Award

Vibhu Sahani | Pharmacology | Lifetime Achievement Award

Published on by World Science Awards

Lifetime Achievement Award

Vibhu Sahani
LLRM Medical College, Meerut
Vibhu Sahani
Affiliation LLRM Medical College, Meerut
Country India
Scopus ID 59031594100
Documents 7
Citations 8
h-index 1
Subject Area Pharmacology
Event World Science Awards

The Lifetime Achievement Award recognizes sustained academic service, scholarly engagement, and professional contributions within a scientific discipline. Vibhu Sahani of LLRM Medical College, Meerut has contributed to the field of pharmacology through research, scholarly publication, and academic activities. The available bibliometric information indicates participation in peer-reviewed scientific communication and ongoing involvement in pharmacological research.[1]

Abstract

Vibhu Sahani is an academic associated with LLRM Medical College, Meerut, India, whose scholarly work is focused on pharmacology. His published research contributes to the understanding of pharmacological science and supports continued advancement in medical research. Available bibliometric indicators, including indexed publications and citations, reflect participation in the international scientific literature and ongoing academic engagement.[1][2]

Keywords

  • Pharmacology
  • Drug Research
  • Medical Science
  • Clinical Pharmacology
  • Biomedical Research
  • Scientific Publications
  • Research Impact
  • World Science Awards

Introduction

Pharmacology is a multidisciplinary scientific field dedicated to understanding the mechanisms, therapeutic applications, efficacy, and safety of medicinal compounds. Research in pharmacology contributes significantly to disease prevention, treatment innovation, and evidence-based healthcare. Academic researchers working in this discipline support advances through laboratory investigations, clinical studies, and scientific publication.[3]

Research Profile

Based on the available Scopus data, Vibhu Sahani has authored seven indexed documents, received eight citations, and holds an h-index of one. These bibliometric indicators demonstrate participation in scholarly research and publication within pharmacology while contributing to the scientific literature through peer-reviewed academic work.[1]

  • Affiliation with LLRM Medical College, Meerut.
  • Primary research area: Pharmacology.
  • Indexed scientific publications: 7.
  • Total citations: 8.
  • Scopus h-index: 1.

Research Contributions

The available publication record indicates contributions to pharmacological investigations and medical science. Research activities in this field support the understanding of therapeutic interventions, drug action, patient care, and evidence-based medicine. Such scholarly contributions form an important part of continued scientific development in healthcare disciplines.[2][3]

Publications

The researcher’s publication portfolio includes peer-reviewed scientific articles indexed within international scholarly databases. These publications demonstrate participation in academic research and dissemination of scientific findings relevant to pharmacology and associated biomedical disciplines.[1]

  • Peer-reviewed journal publications.
  • Pharmacological and biomedical research.
  • Scientific collaboration and academic dissemination.
  • Indexed scholarly contributions.

Research Impact

Research impact is commonly evaluated through publication output, citation performance, scholarly visibility, and contribution to scientific knowledge. The available metrics indicate that Vibhu Sahani has established an indexed research presence in pharmacology. These bibliometric indicators provide objective evidence of participation in scholarly communication while supporting continued academic development.[1]

Award Suitability

Based on the information provided, Vibhu Sahani demonstrates academic engagement through research publication, institutional affiliation, and contributions to pharmacology. Consideration for recognition within the World Science Awards may acknowledge sustained scholarly participation and professional service. Final award decisions should be based on the complete evaluation criteria established by the organizing committee, including academic achievements, research quality, professional experience, and broader scientific contributions.[1][2]

Conclusion

Vibhu Sahani has contributed to pharmacological research through scholarly publication and academic engagement at LLRM Medical College, Meerut. His indexed research record reflects participation in scientific communication and supports ongoing advancement within the biomedical sciences. The documented academic profile provides an objective overview of research activity relevant to professional recognition in the scientific community.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Vibhu Sahani, Author ID 59031594100. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59031594100
  2. World Science Awards. (n.d.). Recognition of scientific excellence through international academic awards.
    https://worldscienceawards.com/
  3. Goodman & Gilman’s. The Pharmacological Basis of Therapeutics.
  4. Nature Reviews Drug Discovery. Drug discovery and pharmacological innovation.
    DOI: https://doi.org/10.1038/nrd.2017.232

Ved Pal | Pharmacology | Innovative Research Award

Published on by World Science Awards

Innovative Research Award

Ved Pal
Affiliation ISF College of Pharmacy, Moga, Punjab
Country India
Scopus ID 59895257200
Documents 3
Citations 5
h-index 1
Subject Area Pharmacology
Event World Science Awards
ORCID 0000-0003-3523-1469

Ved Pal
ISF College of Pharmacy, Moga, Punjab, India

The Innovative Research Award recognizes researchers whose scholarly activities demonstrate sustained commitment to scientific advancement, innovation, and academic excellence. VED PAL, affiliated with ISF College of Pharmacy, Moga, Punjab, has established an academic profile in the field of pharmacology through research contributions, professional engagement, and participation in internationally recognized scholarly platforms.[1]

Abstract

VED PAL is an academic researcher associated with ISF College of Pharmacy, Moga, Punjab, India. His scholarly interests are centered on pharmacology, an interdisciplinary field that integrates pharmaceutical sciences, biomedical research, and therapeutic innovation. His academic profile reflects ongoing engagement with scientific publication, research dissemination, and professional development within the pharmaceutical sciences.[1][2]

Keywords

Pharmacology, Pharmaceutical Sciences, Drug Research, Biomedical Science, Therapeutics, Academic Research, Scientific Publications, Innovation, World Science Awards, Healthcare Research.

Introduction

Pharmacology remains one of the most significant scientific disciplines supporting healthcare innovation through the study of medicines, therapeutic mechanisms, and biological responses. Researchers working in this field contribute toward improving evidence-based healthcare, advancing pharmaceutical technologies, and supporting interdisciplinary scientific collaboration. Academic recognition programs acknowledge these contributions by evaluating research quality, scholarly productivity, and scientific impact using internationally recognized academic indicators.[2][3]

Research Profile

VED PAL is affiliated with ISF College of Pharmacy in Punjab, India, where his academic interests align with pharmacological research and pharmaceutical sciences. His scholarly identity is represented through internationally recognized researcher identifiers, including a Scopus Author ID and an ORCID profile, supporting transparency in research attribution and academic visibility.[1][4]

Research Contributions

Research activities in pharmacology typically involve investigations related to drug discovery, therapeutic evaluation, pharmacodynamics, pharmacokinetics, toxicology, and clinical relevance. Through academic participation and publication activities, VED PAL contributes to the broader scientific dialogue supporting pharmaceutical research and evidence-driven healthcare. Such contributions encourage collaboration between academic institutions and the scientific community while promoting responsible research practices.[2][5]

Publications

The researcher’s scholarly output is indexed through the Scopus author profile associated with Author ID 59895257200. Publication records, citation data, and bibliographic information are maintained through recognized academic indexing systems, allowing researchers and institutions to monitor scientific productivity and collaboration.[1]

Research Impact

Research impact extends beyond publication volume and includes scientific influence, collaboration, knowledge dissemination, and practical application of research findings. International researcher identifiers such as ORCID and Scopus improve research discoverability, strengthen scholarly communication, and facilitate accurate attribution across academic databases. These systems support transparent evaluation of academic achievements within the global research ecosystem.[1][4]

Award Suitability

The Innovative Research Award recognizes researchers demonstrating commitment to scholarly excellence, ethical research practices, scientific innovation, and meaningful contributions within their discipline. Based on the available academic identifiers, institutional affiliation, and specialization in pharmacology, VED PAL represents a researcher whose profile aligns with the objectives of recognizing ongoing scientific engagement and academic development through the World Science Awards.[5]

Conclusion

VED PAL’s academic profile reflects continued participation in pharmaceutical research and international scholarly communication. Through institutional affiliation, recognized researcher identifiers, and engagement with pharmacological sciences, the profile illustrates a commitment to research integrity, scientific advancement, and professional development. Recognition through the Innovative Research Award highlights the importance of sustained contributions to contemporary scientific research while encouraging future innovation within the pharmaceutical sciences.[1][5]

References

  1. Elsevier. (n.d.). Scopus Author Details: VED PAL, Author ID 59895257200. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59895257200
  2. Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2023). Goodman & Gilman’s The Pharmacological Basis of Therapeutics.
    DOI: https://doi.org/10.1038/s41573-021-00234-4
  3. World Health Organization. (n.d.). Research for Health.
    https://www.who.int
  4. ORCID. (n.d.). ORCID Record: 0000-0003-3523-1469.
    https://orcid.org/0000-0003-3523-1469
  5. World Science Awards. (n.d.). Award Evaluation and Recognition Framework.
    https://worldscienceawards.com/

Antra Chaudhary | Pharmaceutical Science | Young Scientist Award

Published on by World Science Awards

Young Scientist Award

Antra Chaudhary,
Jamia Hamdard University, New Delhi, India.

Antra Chaudhary
Affiliation Jamia Hamdard University
Country India
Scopus ID 57406830100
Documents 10
Citations 119
h-index 5
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event World Science Awards
ORCID 0009-0006-9003-5566

Antra Chaudhary is an Indian pharmacology researcher and doctoral scholar recognized for her contributions to bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection research. Her academic work has focused extensively on translational pharmacological approaches involving medicinal plants, osteoporosis therapeutics, neuroinflammation, stem cell-based therapies, and molecular signaling pathways associated with disease progression and tissue protection.[1] She is currently pursuing doctoral research at Jamia Hamdard University under the supervision of Prof. Divya Vohora, where her investigations explore the therapeutic potential of natural compounds against glucocorticoid-induced bone damage and postmenopausal osteoporosis.[2]

Abstract

This academic article presents a scholarly overview of the research contributions, scientific achievements, and professional development of Antra Chaudhary, a pharmacology researcher specializing in bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection. Her research has contributed to understanding molecular signaling pathways associated with osteoporosis, ischemic stroke, rheumatoid arthritis, and mitochondrial dysfunction. Through interdisciplinary pharmacological investigations involving in vitro and in vivo models, her work has emphasized translational therapeutic strategies and the use of bioactive compounds for disease modulation.[3] The article further documents her academic qualifications, awards, technical expertise, scientific publications, and suitability for academic recognition in the field of pharmacology and biomedical sciences.

Keywords

Bone Pharmacology, Oxidative Stress, Osteoporosis, Pharmacology, Neuroprotection, Medicinal Plants, Inflammatory Diseases, Stem Cell Therapy, Molecular Pharmacology, Translational Research, Rheumatoid Arthritis, Glucocorticoid-Induced Bone Damage, Pharmacodynamics, Biomedical Sciences.

Introduction

Contemporary pharmacological research increasingly emphasizes translational approaches that integrate molecular biology, therapeutic intervention, and clinical applicability. Researchers in pharmacology are actively investigating novel compounds and signaling pathways to address chronic diseases, neurodegeneration, inflammatory disorders, and metabolic dysfunctions.[4] Within this scientific landscape, Antra Chaudhary has contributed to emerging research areas involving osteoporosis therapeutics, oxidative stress modulation, neuroinflammation, and medicinal plant-based pharmacological interventions.

Her academic journey reflects a progression through pharmaceutical sciences and toxicology training, supported by competitive national examinations including GPAT and NIPER-JEE. She has participated in multidisciplinary research projects and advanced laboratory investigations utilizing molecular, histological, and imaging-based techniques for experimental pharmacology studies.[5]

Research Profile

Antra Chaudhary completed her Master of Science in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, where she worked on medicinal plant extracts from North-East India for inflammatory disease research. Her doctoral research at Jamia Hamdard University focuses on bone pharmacology and oxidative stress biology under the supervision of Prof. Divya Vohora.[2]

Her technical expertise encompasses a broad range of experimental methodologies, including Western blotting, RT-PCR, immunohistochemistry, fluorescence microscopy, micro-computed tomography, small animal imaging, and cell culture systems. She has also demonstrated competence in pharmacological data analysis using GraphPad Prism and image analysis software.[3]

  • DST WISE KIRAN Fellow for doctoral research in Life Sciences.
  • Qualified GPAT and NIPER-JEE examinations with competitive national rankings.
  • Recipient of the Young Investigator Award 2025 at IPC-IPSCON 2025.
  • Contributor to peer-reviewed journals in pharmacology and neuroscience.

Research Contributions

The scientific contributions of Antra Chaudhary span multiple pharmacological domains, including neuroprotection, osteoporosis, inflammatory signaling, and mitochondrial biology. Her collaborative studies have investigated the role of cardiolipin-mediated mitochondrial protection in ischemic stroke and the therapeutic implications of stem cell-mediated inflammasome modulation.[1]

Her work on bone-targeted daidzein-loaded hydroxyapatite nanoparticles evaluated osteogenic potential and pharmacodynamic activity in postmenopausal osteoporosis models, highlighting nanotechnology-assisted therapeutic delivery systems.[8] Additionally, she contributed to research exploring TLR4/NF-κB and Keap1/Nrf2 signaling pathways in rheumatoid arthritis using perillyl alcohol interventions.[2]

Her review publications further discuss CRISPR/Cas9 technologies in neurological disorders, drug repurposing strategies for stroke intervention, and glial cell responses in neurodegenerative conditions.[5]

Publications

Selected Research Articles

  1. Gautam N, Sharma P, Chaudhary A, et al. Investigating the osteogenic potential of bone-targeted daidzein loaded hydroxyapatite nanoparticles for postmenopausal osteoporosis. Journal of Drug Targeting, 2025.
  2. Sarmah D, Sarkar A, Datta A, et al. Cardiolipin-mediated alleviation of mitochondrial dysfunction is a neuroprotective effect of statin in ischemic stroke. ACS Chemical Neuroscience, 2023.
  3. Puppala ER, Jain S, Saha P, et al. Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways. Phytomedicine, 2022.

Review Articles

  • Advancement in CRISPR/Cas9 technology to better understand and treat neurological disorders.
  • Drug repurposing for stroke intervention.
  • Glial cells response in stroke.

Research Impact

The research contributions of Antra Chaudhary demonstrate interdisciplinary relevance across pharmacology, neuroscience, and biomedical sciences. Her publications address clinically significant challenges associated with osteoporosis, ischemic stroke, inflammatory diseases, and oxidative stress-mediated tissue injury.[11]

Her collaborative work in molecular pharmacology and translational therapeutics contributes to ongoing scientific efforts aimed at developing safer and more effective treatment strategies. The integration of medicinal plant research, nanotechnology-based drug delivery systems, and cellular signaling investigations highlights the translational significance of her scientific profile.[2]

Award Suitability

Antra Chaudhary’s academic profile reflects sustained engagement in experimental pharmacology, translational biomedical research, and scientific dissemination through peer-reviewed publications and conference presentations. Her recognition through the Young Investigator Award at IPC-IPSCON 2025 further demonstrates professional acknowledgment of her contributions within the pharmacological research community.[3]

Her expertise in advanced laboratory techniques, coupled with her publication record and participation in international scientific activities, supports her suitability for academic recognition in the field of pharmacology and bone research. The interdisciplinary scope of her work aligns with contemporary priorities in therapeutic innovation and disease prevention.

Conclusion

Antra Chaudhary represents an emerging researcher in pharmacology whose scientific activities encompass bone pharmacology, oxidative stress biology, neuroprotection, and translational therapeutics. Through experimental research, scholarly publications, and active participation in scientific conferences, she has contributed to advancing knowledge in multiple biomedical domains. Her work continues to support the development of innovative therapeutic approaches aimed at improving disease management and bone health outcomes.[1]

References

  1. Jamia Hamdard University. (2026). Doctoral Research Profile of Antra Chaudhary.
  2. Jamia Hamdard University. (2026). Bone Pharmacology and Oxidative Stress Research Program.
  3. Elsevier. (2025). Pharmacological approaches in osteoporosis and translational therapeutics.
  4. Drug Discovery Today. (2022). Drug repurposing for stroke intervention.
    https://doi.org/10.1016/j.drudis.2022.03.014
  5. National Institute of Pharmaceutical Education and Research. (2020). MS Research Project Documentation.

Mohmmad Younus Wani | Medicinal Chemistry | Excellence in Research Award

Published on by World Science Awards

Assoc. Prof. Dr. Mohmmad Younus Wani | Medicinal Chemistry | Excellence in Research Award

University of Jeddah, Saudi Arabia

Assoc. Prof. Dr. Mohmmad Younus Wani is an accomplished Associate Professor at the University of Jeddah, specializing in medicinal and organic chemistry with a strong focus on drug discovery and antimicrobial resistance. His research centers on the development of small molecule inhibitors and innovative therapeutic strategies to combat drug-resistant pathogens and hospital-acquired infections. With over 90 high-impact publications, an h-index of 33, and more than 4,100 citations, he has established a significant global research presence. Dr. Wani has secured multiple competitive research grants, including major funded projects as Principal Investigator, and holds several US patents in antifungal therapeutics. He has extensive international research experience, having worked in the United States, Portugal, and India, and actively collaborates across multidisciplinary teams. His work contributes to advancing healthcare solutions and addressing critical global challenges in infectious diseases and antimicrobial resistance.

Citation Metrics (Scopus)

3500
2500
1500
500

Citations
3,152

h-index
29

Documents
92

Citations

h-index

Documents

Featured Publications

MA Malik, MY Wani, MA Hashim (2012).
Microemulsion method: A novel route to synthesize organic and inorganic nanomaterials: 1st Nano Update
Arabian Journal of Chemistry | Journal Article · 2012 · 📊 Citations: 864

MA Malik, OA Dar, P Gull, MY Wani, AA Hashmi (2018).
Heterocyclic Schiff base transition metal complexes in antimicrobial and anticancer chemotherapy
MedChemComm | Journal Article · 2018 · 📊 Citations: 459

S Kumar, MY Wani, CT Arranja, JA e Silva, B Avula, AJFN Sobral (2015).
Porphyrins as nanoreactors in the carbon dioxide capture and conversion: a review
Journal of Materials Chemistry A | Journal Article · 2015 · 📊 Citations: 161

MA Malik, MY Wani, SA Al-Thabaiti, RA Shiekh (2014).
Tetrazoles as carboxylic acid isosteres: chemistry and biology
Journal of Inclusion Phenomena and Macrocyclic Chemistry | Journal Article · 2014 · 📊 Citations: 161

MY Wani, MA Hashim, F Nabi, MA Malik (2011).
Nanotoxicity: dimensional and morphological concerns
Advances in Physical Chemistry | Journal Article · 2011 · 📊 Citations: 136

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Jiunn-Liang Ko | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Jiunn-Liang Ko | Pharmaceutical Science | Research Excellence Award

Chung Shan Medical University | Taiwan

Dr. Jiunn-Liang Ko is a distinguished scholar in the fields of biochemistry, toxicology, and medical sciences, with a research career spanning more than three decades. He earned his Ph.D. in Biochemistry from the College of Medicine at National Taiwan University (1995), following a Master’s and Bachelor’s degree in Biology from Fu-Jen University. His academic and scientific journey reflects unwavering dedication to advancing biomedical research, particularly in molecular toxicology, environmental health, and translational medicine. Dr. Ko began his professional research career as a Postdoctoral Fellow at the Taiwan Agricultural Chemicals and Toxic Substances Research Institute, where he contributed to pioneering work in biopesticide safety and toxicological mechanisms. In 2003, he joined Chung-Shan Medical University, where he progressed from Professor in the Institute of Toxicology to Director of multiple strategic units, including the Research & Development Office, the Instrumental Center, and the Institute of Medical and Molecular Toxicology. His leadership has been instrumental in enhancing interdisciplinary research capacity, laboratory infrastructure, and academic excellence at the institution. Since 2011, Dr. Ko has served as Professor at the Institute of Medicine at Chung-Shan Medical University, continuing to lead high-impact research, mentor scholars, and foster international collaborations. His work encompasses molecular carcinogenesis, toxicogenomics, and the cellular responses to environmental hazards, positioning him as a key contributor to advancing understanding of public health risks and disease prevention. Over his career, he has authored numerous peer-reviewed publications, contributed to national and international projects, and collaborated across academia, healthcare, and applied science sectors. His research outputs are recognized for their scientific rigor and real-world relevance, influencing policy, clinical practice, and biosafety standards. Through his sustained academic leadership, scientific innovation, and commitment to education, Dr. Jiunn-Liang Ko continues to contribute significantly to global biomedical research and the advancement of public health.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Yang, Y.-T., Hsu, C.-H., Wang, Y.-F., Chang, Y.-J., Yang, H.-J., Ko, J.-L., & Yang, K.-C. (2022). Worsening quality of life in young adult, highly educated, and married female patients with vitiligo: A hospital-based case control study in Taiwan. International Journal of Environmental Research and Public Health, 19(11), 6741.

Chang, J.-C., Chiou, J.-Y., Ko, J.-L., Huang, J.-Y., & Lue, K.-H. (2021). Early bronchiolitis contributes to preschool asthma. Children, 8(12), 1176.

Hsin, I.-L., Shen, H.-P., Chang, H.-Y., Ko, J.-L., & Wang, P.-H. (2021). Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 positive feedback loop induces cell cycle arrest by dual PI3K/mTOR inhibitor PQR309 in endometrial cancer cell lines. Cells, 10(11), 2916.

Hsiao, Y.-P., Chen, H.-L., Tsai, J.-N., Lin, M.-Y., Liao, J.-W., Wei, M.-S., Ko, J.-L., & Ou, C.-C. (2021). Administration of Lactobacillus reuteri combined with Clostridium butyricum attenuates cisplatin-induced renal damage by gut microbiota reconstitution, increasing butyric acid production, and suppressing renal inflammation. Nutrients, 13(8), 2792.

Wu, S.-W., Ko, J.-L., Liu, B.-H., & Yu, F.-Y. (2020). A sensitive two-analyte immunochromatographic strip for simultaneously detecting aflatoxin M1 and chloramphenicol in milk. Toxins, 12(10), 637.

Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Published on by World Science Awards

Dr. Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Wayne State University | United States

Dr. Omid Mehrpour is a distinguished medical toxicologist, clinical data scientist, and physician whose work integrates toxicology, public health, and artificial intelligence to advance diagnostic accuracy and patient outcomes. With over two decades of academic, clinical, and research experience, he has become an internationally recognized expert in poisoning, substance use disorders, and AI-driven medical decision-making. Dr. Mehrpour has authored more than 200 peer-reviewed articles, ten book chapters, and a book translation, accumulating over 4,000 scientific citations. His publications and research outputs have significantly shaped clinical toxicology guidelines globally, particularly in areas related to opioids, heavy metals, aluminum phosphide, cannabinoids, and environmental toxicants. A pioneer in AI-based diagnostic innovation, Dr. Mehrpour developed machine learning–driven protocols for poison diagnosis, leading to two registered U.S. patents and additional patents in Iran for diagnostic software and toxicology devices. His work at the Rocky Mountain Poison & Drug Safety Center and collaborations with national databases such as NPDS and ToxIC contributed foundational methods for rapid identification and triage of poisoning cases. He has also led AI and clinical informatics initiatives at the University of Colorado Anschutz Medical Campus and founded AI and Health LLC to develop intelligent clinical tools that enhance diagnosis and care delivery. Throughout his career, Dr. Mehrpour has held leadership roles including Head of the Medical Toxicology and Drug Abuse Research Center and Director of the Poisoning Ward at Birjand University of Medical Sciences. He has supervised numerous graduate researchers and served on editorial boards of multiple international journals. His contributions have received global recognition, including placement among the top 2% of scientists worldwide, multiple “Top Reviewer” honors from Publons, and numerous national research awards. Dr. Mehrpour’s work continues to elevate the fields of toxicology, predictive modeling, and precision medicine, contributing impactful solutions that improve healthcare systems and advance patient safety worldwide.

Profiles: Scopus | ORCID

Featured Publications

1. Eizadi-Mood, N., Barzam, E., Pirali, Z., Feizi, A., Namvar, M., Abdi, E., Mirmoghtadaee, P., Mehrpour, O., & Meamar, R. (2025). Gender differences in opioid and stimulant poisoning in the central region of Iran: A cross-sectional study. Scientific Reports.

2. Amrollahi-Sharifabadi, M., Oladejo, T. O., Ibrahim, A. S., Shakoor, B., Mehrpour, O., Sadeghi-Hashjin, G., & Gonçalves, S. (2025). Melatonin’s paradox: From therapeutic benefits to toxicity warnings. Chemico-Biological Interactions, 111556.

3. Kooshki, A., Mansouri, B., Farmani, R., Amirabadizadeh, A., Mehrpour, O., Sanjari, M. J., & Nakhaee, S. (2024). Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PLOS ONE, 19(12), e0313851.

4. Mehrpour, O., & Sadeghi, M. (2024). The occurrence of unusually cold weather could contribute to the incidence of carbon monoxide poisoning. Clinical and Experimental Emergency Medicine.

5. Nakhaee, S., Kooshki, A., Hormozi, A., Akbari, A., Mehrpour, O., & Farrokhfall, K. (2023). Cinnamon and cognitive function: A systematic review of preclinical and clinical studies. Nutritional Neuroscience.

Sa Xiao | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Sa Xiao | Pharmaceutical Science | Best Researcher Award

Chief Pharmacist, Clinical pharmacist from The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, China

Sa Xiao is an experienced Clinical Pharmacist currently working at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China. she has dedicated her career to clinical pharmacy with a focus on providing quality patient care and optimizing pharmaceutical practices. Sa Xiao holds a Master’s degree in Pharmacology and a Bachelor’s degree in Pharmaceutical Engineering. Over the past five years and seven months, she has consistently contributed to clinical pharmacy, focusing on improving therapeutic outcomes and pharmaceutical interventions. Sa Xiao’s role places her at the intersection of clinical application and pharmaceutical research, where she works to enhance drug therapy effectiveness and patient safety. Her work contributes directly to hospital-based pharmaceutical care and supports interdisciplinary collaboration in medical settings. Sa Xiao’s background equips her with both theoretical knowledge and practical clinical experience, positioning her as a valuable asset in the healthcare system. While her current profile emphasizes her clinical expertise, expanding her research portfolio could further elevate her impact in the pharmaceutical field. Her dedication, professional growth, and potential for further research contributions make her a promising candidate for recognition in her domain.

Professional Profile

Education

Sa Xiao has built a strong academic foundation that supports her professional excellence in clinical pharmacy. She began her higher education journey at Huzhou Normal University, where she pursued a Bachelor’s degree in Pharmaceutical Engineering from September 2012 to June 2016. This program provided her with essential knowledge of pharmaceutical sciences, drug formulation, and pharmaceutical manufacturing processes. Her education at this stage focused on understanding drug properties, production, and the basic principles that guide pharmaceutical development. After completing her undergraduate studies, Sa Xiao advanced her academic qualifications by enrolling in Guangdong Medical University, where she earned her Master’s degree in Pharmacology from September 2016 to June 2019. This graduate program allowed her to delve deeper into the study of drug actions, mechanisms, and pharmacokinetics. Through her Master’s studies, she developed a comprehensive understanding of clinical pharmacology, which now directly supports her work as a clinical pharmacist. Both her degrees are recognized by the Ministry of Education, China, affirming the academic rigor and credibility of her educational background. Her academic journey demonstrates a seamless transition from pharmaceutical engineering to clinical application, providing her with the necessary expertise to excel in both pharmaceutical sciences and patient-centered clinical practice.

Professional Experience

Sa Xiao has gained substantial professional experience as a Clinical Pharmacist, holding this role since July 2019 at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology. With over five years of experience, she has developed a deep understanding of clinical pharmacy operations, patient care protocols, and hospital pharmaceutical services. Her responsibilities likely include reviewing prescriptions, optimizing medication therapies, ensuring the safe and effective use of drugs, and collaborating with medical teams to enhance patient outcomes. Working in a hospital affiliated with a reputable university has provided her with exposure to clinical research, medical education, and interdisciplinary cooperation. Sa Xiao’s experience is not limited to routine pharmacy tasks; her role also requires ongoing learning and adaptation to the latest pharmaceutical guidelines and therapeutic advancements. Her career has been characterized by dedication to improving patient care and supporting evidence-based clinical decisions. While her profile currently focuses on clinical responsibilities, there is potential for her to expand her contributions to include scientific publications, research studies, and leadership in pharmaceutical innovations. Her professional track record reflects commitment, consistency, and the ability to thrive in a demanding healthcare environment.

Research Interest

Sa Xiao’s research interests are rooted in clinical pharmacy and pharmacology, with a focus on optimizing drug therapies, enhancing patient safety, and improving pharmaceutical care within hospital settings. Her academic and professional background suggests a strong interest in therapeutic drug monitoring, drug interactions, and evidence-based medication management. She is likely driven to explore methods for improving the clinical efficacy of pharmacological treatments and minimizing adverse drug reactions. Additionally, she may be interested in research concerning personalized medicine, dosage adjustments for specific patient populations, and clinical outcomes related to pharmaceutical interventions. Her experience as a clinical pharmacist positions her to contribute valuable insights into hospital-based drug management, prescription review processes, and the practical challenges faced in clinical settings. Future research could also include comparative studies on the effectiveness of different pharmacological treatments and the implementation of clinical pharmacy protocols to improve patient care. By aligning her clinical expertise with focused research initiatives, Sa Xiao has the potential to contribute to both national and international discussions in the field of clinical pharmacology and pharmacy practice. Expanding her research interests to cover these areas would significantly strengthen her academic and professional profile.

Research Skills

Sa Xiao possesses a range of research skills that align with her clinical pharmacy background. Her academic training in pharmacology provided her with expertise in drug action mechanisms, pharmacokinetics, and pharmacodynamics, which are essential for conducting clinical pharmaceutical research. She likely has experience in analyzing clinical data, reviewing case studies, and evaluating therapeutic outcomes in real-world settings. Her role as a clinical pharmacist has refined her skills in prescription auditing, patient counseling, and drug therapy evaluation, which contribute to her ability to design practical, patient-focused research projects. Sa Xiao is also expected to be proficient in using clinical databases, medical literature review systems, and pharmacovigilance tools to support her clinical decision-making and potential research activities. Moreover, she may have developed collaborative skills through working with interdisciplinary teams, which are critical for conducting joint clinical studies and implementing hospital-wide pharmaceutical protocols. To further enhance her research portfolio, acquiring advanced skills in statistical analysis, research methodology, and scientific writing would be beneficial. By building on her current skill set and actively participating in research dissemination through conferences and publications, Sa Xiao can establish herself as a leading contributor in the clinical pharmacy research community.

Awards and Honors

At present, no specific awards or honors have been provided for Sa Xiao. However, her sustained commitment to clinical pharmacy over a period of more than five years at a leading university hospital reflects her professional reliability and growing expertise. Although formal recognitions such as research awards, clinical excellence distinctions, or academic honors have not yet been documented, Sa Xiao’s continuous role in a competitive healthcare environment signifies institutional trust in her capabilities. It is possible that she has received internal recognition for her contributions to patient care, medication management, or quality improvement initiatives within her department. Engaging in national or international pharmaceutical competitions, participating in recognized clinical research projects, and contributing to peer-reviewed publications could open avenues for future awards and honors. Earning formal recognition would not only validate her contributions but also help strengthen her professional profile for broader scientific and clinical acknowledgment. Sa Xiao’s consistent career growth and practical impact within the hospital setting suggest that she is well-positioned to achieve significant honors as she continues to expand her involvement in clinical research and professional development activities in the future.

Conclusion

In conclusion, Sa Xiao is a highly capable clinical pharmacist with a strong educational background and valuable experience in the hospital pharmaceutical sector. Her work at The Sixth Affiliated Hospital, School of Medicine, South China University of Technology demonstrates her ability to apply pharmacological knowledge in a clinical environment, directly benefiting patient care and therapeutic practices. While her current profile is predominantly clinical, there is significant potential for her to make substantial research contributions to the field of clinical pharmacy and pharmacology. Sa Xiao’s foundation in pharmaceutical engineering and pharmacology equips her with both theoretical and practical expertise, which can be further advanced through scientific publications, conference presentations, and research collaborations. By actively participating in research dissemination and seeking broader recognition through professional awards, she can enhance her influence within the scientific and medical communities. Sa Xiao’s dedication, clinical precision, and future research potential position her as an emerging contributor to the advancement of pharmaceutical care and clinical pharmacy research. With further academic engagement and research output, she is likely to achieve greater professional recognition and make impactful contributions to the global healthcare landscape.

Publications Top Notes

1. Depression and Suicide/Self-Injury Signals for Weight Loss Medications: A Disproportionality Analysis of Semaglutide, Liraglutide, and Tirzepatide in FAERS Database

  • Journal: Journal of Affective Disorders

  • Publication Date: 2025-06-14

  • Authors: Wang M, Yang Z, Yan M, Liu S, Xiao S

2. Protective Effects of Aqueous Extract of Wampee Fruit Against Anti-Tubercular Drug-Induced Hepatotoxicity in Rats

  • Journal: Journal of Biological Regulators and Homeostatic Agents

  • Publication Date: 2019-01-01

  • Authors: Guan TM, Xiao S, Liu DC, Liao XH, Li WD, Wu KF, Huang R

 

Phuong Linh Ta | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Ms. Phuong Linh Ta | Pharmaceutical Science | Best Researcher Award

University CEU CArdenal Herrera, Spain

Phuong Linh Ta is an emerging researcher in the field of pharmacology, currently pursuing her doctoral studies at Universidad Cardenal Herrera CEU in Spain. She is a highly motivated scientist with a solid academic foundation and practical experience in pharmaceutical research, particularly focusing on ocular drug delivery systems and antibiotic discovery. Throughout her career, she has actively contributed to impactful projects that address pressing global health concerns, such as the development of new antibiotics and the prevention of cognitive decline associated with diseases like Alzheimer’s. She has consistently demonstrated a passion for contributing to both scientific advancement and community well-being through her involvement in various outreach programs including elderly care and sustainable development challenges. Phuong Linh Ta’s scientific journey is marked by a balanced integration of academic excellence, innovative research, and social engagement. Her participation in prestigious conferences across Europe has allowed her to present her work to the international scientific community, thereby expanding her professional network and research visibility. With her commitment to continuous learning, interdisciplinary collaboration, and practical applications in the pharmaceutical field, Phuong Linh Ta is steadily building a robust research portfolio that holds promise for future breakthroughs in pharmacology and clinical applications.

Professional Profile

Education

Phuong Linh Ta’s educational background showcases a steady progression in pharmaceutical sciences and clinical research. She completed her Master’s degree in Direction and Monitorization of Clinical Trials from Universidad Cardenal Herrera CEU in 2022, equipping her with specialized knowledge in clinical trial design and pharmaceutical study management. Prior to that, she earned her Bachelor’s degree in Pharmacy from the same university in 2021, which provided her with a strong foundation in pharmacological principles, drug formulation, and patient care. She also participated in the Forster Summer School at the University of Mainz in 2019, where she gained international exposure and broadened her academic perspective. Her early academic journey includes completing the International Baccalaureate at Birkerød Gymnasium, HF, IB & Boarding School in Denmark, which highlights her global educational experience. This diverse and international academic pathway has given her a broad cultural and scientific outlook, enhancing her adaptability and communication across different educational and professional environments. Her formal education has been consistently aligned with her research interests, particularly in clinical pharmacology, drug delivery systems, and public health, positioning her well for her doctoral research and future contributions to the pharmaceutical sector.

Professional Experience

Phuong Linh Ta has developed substantial professional experience through various academic roles at Universidad Cardenal Herrera CEU. She is currently engaged as a doctoral student in the Faculty of Pharmacy, focusing on pharmacology research, with her work beginning in November 2022. Her previous roles include serving as a Pharmacy Classroom Assistant, where she provided educational support and facilitated learning for undergraduate students. Additionally, she worked as an Internal Student in the Department of Pharmacology, where she honed her laboratory and research skills through hands-on involvement in pharmaceutical studies. Her collaborative roles in the departments of Languages and Communication further enriched her interpersonal, administrative, and organizational capabilities, demonstrating her versatility and commitment to contributing to different facets of the university environment. These experiences have provided her with a well-rounded understanding of both research and academic operations, preparing her for independent and collaborative work in complex scientific projects. Her sustained professional engagement within the same institution illustrates her reliability, long-term dedication, and growth within the academic community. Her evolving responsibilities have enabled her to build a solid foundation in both teaching and research, setting the stage for her continued contributions to the field of pharmacology.

Research Interest

Phuong Linh Ta’s primary research interests lie at the intersection of pharmacology, drug delivery systems, and clinical applications aimed at improving patient outcomes. She is particularly focused on the development of ocular drug delivery platforms, including the formulation and characterization of ocular inserts to enhance the bioavailability and targeted release of therapeutic agents. Her recent research has concentrated on using alpha-lipoic acid in beta-cyclodextrin complexes for improved delivery to the posterior segment of the eye, which holds significant potential for the treatment of ocular diseases and the prevention of long-term complications associated with high myopia. Additionally, she has been involved in projects that address global health challenges such as the discovery of new antibiotics and the promotion of their rational use, aligning her work with the global fight against antimicrobial resistance. Her interest extends to neuroprotective strategies for the early prevention of cognitive deterioration, reflecting her multidisciplinary approach that bridges pharmaceutical technology with public health priorities. Phuong Linh Ta’s research is deeply rooted in translating laboratory findings into practical healthcare solutions, and she is committed to advancing drug delivery science to make therapeutics more efficient, accessible, and patient-centered.

Research Skills

Phuong Linh Ta possesses a diverse range of research skills that are crucial to her contributions in pharmaceutical sciences. She is proficient in developing and characterizing drug delivery systems, particularly ocular inserts, and has significant experience in in vitro release studies and ex vivo diffusion studies. Her technical expertise includes working with complex molecular assemblies like beta-cyclodextrin complexes, optimizing drug stability and bioavailability. She is skilled in conducting clinical trials, managing pharmacological experiments, and applying service-learning methodologies in educational and research settings. Her involvement in competitive R&D projects has also equipped her with skills in project planning, data analysis, and scientific reporting. Furthermore, she has effectively communicated her research findings at multiple international conferences, indicating her capability in scientific presentation and knowledge dissemination. Phuong Linh Ta’s multilingual abilities—fluency in Vietnamese, Spanish, and English—further enhance her collaborative potential in diverse research environments. Her capacity to integrate laboratory research with clinical applications and her aptitude for both independent and team-based work make her a versatile and competent researcher. She continuously seeks to refine her laboratory techniques, analytical skills, and knowledge of pharmacological systems to remain at the forefront of her field.

Awards and Honors

As of the current stage of her career, Phuong Linh Ta’s recognition is primarily reflected in her selection for multiple competitive research projects and her invitations to present at prestigious scientific conferences across Europe. She has actively participated in national and international conferences such as EVER, the Controlled Release Society (CRS) Annual Meeting, and the Spanish-Portuguese Conference on Controlled Drug Delivery. These platforms have provided her with opportunities to showcase her research and gain valuable feedback from global experts. Her consistent involvement in the SWI@CEU project and the DeCo MICOF-CEU project demonstrates the trust her academic institution places in her research capabilities. While she has not yet accumulated formal awards or fellowships, her current academic track record and research engagement highlight her potential for future recognition and academic distinction. Participation in such competitive and high-impact research initiatives serves as an important professional milestone, indicating her emerging status within the scientific community. Moving forward, continued success in publishing peer-reviewed articles and leading independent research projects will likely pave the way for her to receive more significant awards, grants, and honors that will further validate her contributions to pharmaceutical sciences.

Conclusion

Phuong Linh Ta is a dedicated and promising researcher who has steadily built a strong foundation in pharmacology and pharmaceutical research through her education, professional experience, and focused scientific contributions. Her work reflects a commitment to developing innovative drug delivery systems, with particular emphasis on ocular therapeutics and public health impact. While her research is still in the early stages, she has already gained substantial international exposure and actively contributed to community-based and service-learning projects. Her technical skills, multilingual proficiency, and ability to collaborate in multidisciplinary teams make her well-prepared to take on more advanced research challenges in the future. Although there are areas for growth, especially in peer-reviewed publications and leadership of independent projects, her trajectory suggests she is on the right path toward becoming a highly impactful researcher. With further development and continued dedication, Phuong Linh Ta has the potential to significantly contribute to advancements in drug delivery, pharmacology, and patient-centered healthcare solutions. Her work is aligned with global health priorities, and she is well-positioned to make meaningful scientific contributions in both academic and clinical contexts.

Publications Top Notes

  • Title: Optimization and Validation of a High‐Performance Liquid Chromatography (HPLC‐UV) Method for Quantification of α‐Lipoic Acid in Cyclodextrins Complex for Ocular Delivery

  • Authors: Phuong Linh Ta, Lucia Bernat‐Just, Adrián M. Alambiaga‐Caravaca, Vicent Rodilla, Alicia López‐Castellano, Francisco Bosch‐Morell

  • Year: 2025

Yongpan An | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Yongpan An | Pharmaceutical Science | Best Researcher Award

Pharmacology Researcher from Xi’an People’s Hospital (Xi’an Fourth Hospital), China

Yongpan An is an emerging researcher in the field of pharmacology, specializing in drug screening and the mechanistic study of aging and aging-related diseases. A recent Ph.D. graduate from Peking University, Dr. An has demonstrated significant promise through his contributions to high-impact research, authoring and co-authoring several peer-reviewed publications. His work spans various disciplines, including molecular biology, artificial intelligence, and pharmacological intervention, reflecting a multidisciplinary approach essential for innovative biomedical research. As of now, he is affiliated with Xi’an People’s Hospital, where he continues to build on his doctoral research. Dr. An has already co-authored influential studies published in journals such as Nature Biotechnology, Aging Cell, Frontiers in Pharmacology, and Life Medicine. Despite being early in his career, his scientific output, collaboration with renowned researchers, and peer review responsibilities signal a strong foundation for a successful academic trajectory. His research addresses a critical area in medical science—aging—and aims to identify compounds that can prolong lifespan and reduce age-associated degeneration. With demonstrated leadership in co-authorship roles and contributions to the understanding of pharmacological interventions for aging, Yongpan An stands out as a dedicated, capable, and innovative young scientist poised for further accomplishments.

Professional Profile

Education

Yongpan An’s academic journey reflects a solid foundation in biotechnology and pharmacology, cultivated through rigorous training at leading Chinese institutions. He began his undergraduate studies in Biotechnology at Yunnan University, where he developed fundamental skills in molecular biology and biochemical research. From 2014 to 2018, he was immersed in coursework and research that exposed him to laboratory techniques and foundational knowledge in life sciences. His pursuit of advanced studies led him to Peking University, one of China’s most prestigious academic institutions, where he obtained his Ph.D. in Pharmacology between 2018 and 2023. At Peking University, under the mentorship of Dr. Zhengwei Xie, he focused on drug screening and the molecular mechanisms underlying aging. During this period, Dr. An gained hands-on experience with advanced pharmacological methodologies, contributing to several high-impact studies. His doctoral training not only equipped him with scientific expertise but also fostered skills in critical thinking, interdisciplinary collaboration, and scientific communication. His research incorporated cutting-edge areas such as the application of artificial intelligence in drug discovery, reinforcing the modern relevance of his education. This academic progression—from biotechnology to pharmacology—provides a robust framework for his current and future research endeavors in aging and age-related diseases.

Professional Experience

Dr. Yongpan An is currently employed at Xi’an People’s Hospital, where he continues to engage in pharmacological research with a focus on aging and age-related diseases. Although early in his professional career, Dr. An has already demonstrated remarkable productivity and leadership in scientific research. During his doctoral studies at Peking University, he was deeply involved in collaborative projects that combined pharmacological experimentation with computational analysis. His work involved both in vivo and in vitro models, providing him with experience across various experimental platforms. In addition to research responsibilities, Dr. An served as a reviewer for the journal Pharmacological Research, evaluating scientific manuscripts and gaining familiarity with the editorial and peer-review process. His professional engagements have also included active participation in scientific conferences and forums, where he presented his findings and interacted with experts in the field of aging and pharmacology. Notably, he played a major role in authoring a comprehensive review titled The Landscape of Aging, where he was responsible for summarizing the application of artificial intelligence in anti-aging drug discovery. As he transitions from a student to an independent researcher, Dr. An continues to demonstrate commitment to excellence, innovation, and scientific rigor in his ongoing professional endeavors.

Research Interests

Dr. Yongpan An’s primary research interests lie in the pharmacological modulation of aging and the discovery of novel compounds targeting aging-related diseases. His work integrates drug screening techniques with the mechanistic study of cellular and organismal aging processes. Specifically, he is interested in understanding how small molecules interact with key molecular pathways, such as the AKT signaling cascade, p16, and cyclin regulatory mechanisms, to delay senescence and promote healthy lifespan extension. Another key area of interest for Dr. An is the use of natural products, such as oridonin and berberine, in regulating cellular aging. His contributions to this field are evident from his publications in high-impact journals that explore the therapeutic potential of such compounds in mouse and yeast models. Additionally, he has contributed to the development of AI-driven tools for predicting drug efficacy from transcriptional profiles, showcasing his interest in computational pharmacology. The integration of artificial intelligence and deep learning with experimental pharmacology highlights his vision of combining traditional experimental approaches with cutting-edge digital methodologies. His overarching goal is to discover and validate compounds that not only extend lifespan but also improve quality of life by mitigating the effects of chronic and degenerative diseases associated with aging.

Research Skills

Dr. Yongpan An possesses a diverse and interdisciplinary set of research skills, developed through years of academic training and hands-on laboratory experience. He is proficient in a wide range of pharmacological and molecular biology techniques, including cell culture, Western blotting, immunofluorescence, RNA extraction, and quantitative PCR. He has extensive experience working with animal models, especially in the context of lifespan and senescence studies in mice and yeast, which are central to his research in aging. His capabilities also include the screening and identification of bioactive compounds using high-throughput methods, allowing him to evaluate the pharmacodynamic and pharmacokinetic properties of candidate molecules. Dr. An is adept at using bioinformatics and artificial intelligence tools to analyze gene expression data and predict drug responses. This skillset was crucial in his involvement in the development of deep learning models for drug efficacy prediction, published in Nature Biotechnology. Moreover, his experience as a peer reviewer reflects his ability to critically assess scientific literature and evaluate experimental design, data quality, and interpretation. His collaborative skills and familiarity with interdisciplinary projects further enhance his research capabilities, making him an asset to both academic and clinical research teams focusing on anti-aging pharmacological interventions.

Awards and Honors

Despite being at the beginning of his career, Dr. Yongpan An has already received several prestigious awards in recognition of his academic excellence and research achievements. During his doctoral studies at Peking University, he was honored with the National Scholarship, a highly competitive award given to outstanding students in China. He also received the First Prize in the Soaring Young Scholar competition held by Northwestern Polytechnical University, which recognizes young researchers for innovative scientific contributions. Additionally, he was awarded the Second Prize at the Young Scientist Forum Report organized by the Beijing Society of Pharmacology and Physiological Sciences, affirming his potential as a promising figure in pharmacological research. These honors not only reflect his dedication to scientific inquiry but also underscore the impact and relevance of his work within the research community. His involvement as a co-first author in significant collaborative publications further demonstrates peer recognition of his scholarly efforts. Beyond awards, his service as a manuscript reviewer for an established journal like Pharmacological Research highlights the trust placed in his scientific judgment. Collectively, these accolades validate Dr. An’s emerging role as a capable and committed young scientist with a promising future in pharmacology and aging research.

Conclusion

In summary, Dr. Yongpan An embodies the qualities of a highly promising early-career researcher with a strong academic foundation, impactful research output, and growing recognition within the scientific community. His work focuses on one of the most critical areas in medical science—understanding and intervening in the aging process to improve human health and longevity. His background in both experimental pharmacology and artificial intelligence places him at the intersection of innovation and translational medicine. Despite his relatively recent graduation, he has already authored multiple first-author publications, participated in high-level collaborative research, and received awards for his contributions. Dr. An’s dedication to advancing the pharmacological understanding of aging-related diseases and his proactive engagement in academic publishing and peer review highlight his scientific maturity. He is currently well-positioned to expand his research, attract future funding, and lead independent projects that will further enhance his professional profile. As he continues to build his research portfolio at Xi’an People’s Hospital, Dr. An is likely to contribute significantly to the development of therapeutic strategies that target aging and its associated disorders. Therefore, he represents an outstanding candidate for recognition through awards that honor excellence in scientific research.

Publications Top Notes

  1. Title: Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy
    Authors: Gao, Ke; Xi, Wenjin; Ni, Jianxin; Zhang, Rui; Wu, Guojun
    Journal: Biomaterials
    Year: 2025